Within our published patient cohort CTCF was sequenced in 172 endometrioid adenocarcinomas and 60 serous carcinomas.5 In all, 16 missense and 25 inactivating mutations (including 17 nonsense and 8 frameshift mutations) were identified (Supplementary Table 2). This evidence concerns the gene CTCF and serous adenocarcinoma.